Previous close | 20.75 |
Open | 20.08 |
Bid | 20.00 x 0 |
Ask | 21.50 x 0 |
Day's range | 20.00 - 21.50 |
52-week range | 20.00 - 40.50 |
Volume | |
Avg. volume | 43,007 |
Market cap | 133.63M |
Beta (5Y monthly) | 1.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.80 |
Earnings date | 03 Mar 2022 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
The big shareholder groups in Allergy Therapeutics plc ( LON:AGY ) have power over the company. Institutions often own...
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two pivotal trials Portfolio focused on high value growth products to enhance future profitabilityGround-breaking Phase I trial of peanut allergy vaccine on track to commence in 2022 following recent FDA clearance of IND application with data expected sooner than previously anticipatedPivotal Phase III trial of short-cou
It hasn't been the best quarter for Allergy Therapeutics plc ( LON:AGY ) shareholders, since the share price has fallen...